Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Behçet’s disease: an algorithmic approach to its treatment

  • 749 Accesses

  • 37 Citations

Abstract

Behçet’s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, gastrointestinal, urogenital, pulmonary, and neurologic involvement. Mucocutaneous lesions figure prominently in the presentation and diagnosis, and may be considered the hallmarks of BD. Therefore, their recognition may permit earlier diagnosis and treatment. Although, the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early and appropriate treatment is mandatory to reduce morbidity and mortality. We reviewed the current state of knowledge regarding the therapeutic approaches for BD and designed a stepwise, symptom-based, algorithmic approach, mainly based on controlled studies and our clinical experience in this field to provide a rational framework for selecting the appropriate therapy along the various treatment choices.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Addy M, Carpenter R, Roberts WR (1976) Management of recurrent aphthous ulceration. A trial of chlorhexidine gel. Br Dent J 141:118–120

  2. 2.

    Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades–Behçet’s disease. Dermatology 203:322–324

  3. 3.

    Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E (2007) Relationship between periodontal findings and Behcet’s disease: a controlled study. J Clin Periodontol 34:485–491

  4. 4.

    Akman A, Sallakci N, Kacaroglu H et al (2008) Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behçet’s disease. J Eur Acad Dermatol Venereol 22(8):950–957

  5. 5.

    Aktulga E, Altac M, Muftuoglu A et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402

  6. 6.

    Alpsoy E (2005) Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 23:532–539

  7. 7.

    Alpsoy E, Akman A (2006) Treatment of Behçet’s disease. Therapy 3:139–151

  8. 8.

    Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E (1998) A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet’s patients. Int J Dermatol 37:839–843

  9. 9.

    Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B (2003) Review of the clinical manifestations’ chronology in 60 patients with Behçet’s disease. Dermatology 117:354–356

  10. 10.

    Alpsoy E, Donmez L, Onder M et al (2007) Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol 157:901–906

  11. 11.

    Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alpha-2a in the treatment of Behçet disease: a randomized, placebo-controlled and double blind study. Arch Dermatol 138:467–471

  12. 12.

    Alpsoy E, Er H, Durusoy C, Yilmaz E (1999) The use of sucralfate suspension in the treatment of oral and genital ulcerations of Behçet’s disease: a randomised, placebo-controlled and double-blind study. Arch Dermatol 135:529–532

  13. 13.

    Alpsoy E, Zouboulis CC, Ehrlich CE (2007) Mucocutaneous lesions of Behçet’s disease. Yonsei Med J 48:573–585

  14. 14.

    Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK (2005) Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 11(3):3

  15. 15.

    Assaad-Khalil SH (1991) Low-dose cyclosporin in Behçet’s disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet’s disease. In: O’Duffy JD, Kokmen E (eds) Behçet’s disease: basic and clinical aspects. Marcel Dekker, New York, pp 603–612

  16. 16.

    Azizlerli G, Kose AA, Sarica R et al (2003) Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol 42:803–806

  17. 17.

    Bacanli A, Yerebakan O, Parmaksizoglu B, Yilmaz E, Alpsoy E (2006) Topical granulocyte-colony stimulating factor for the treatment of oral and genital ulcers of patients with Behçet’s disease. J Eur Acad Dermatol Venereol 20:931–935

  18. 18.

    Bang D (1997) Treatment of Behcet’s disease. Yonsei Med J 38:401–410

  19. 19.

    BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transplant Proc 20:136–143

  20. 20.

    Binnie WH, Curro FA, Khandwala A, Van Inwegan RG (1997) Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 18:1116–1124

  21. 21.

    Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 192:125–128

  22. 22.

    Conklin RJ, Blasberg B (1991) Common inflammatory diseases of the mouth. Int J Dermatol 30:323–335

  23. 23.

    Davatchi F, Shahram F, Chams H, Akbarian M (1999) Pulse cyclophosphamide (PCP) for ocular lesions of Behçet’s disease: double blind crossover study. Arthritis Rheum 42:S320

  24. 24.

    Davatchi F, Shahram F, Chams H et al (2003) High dose methotrexate for ocular lesions of Behçet’s disease. Preliminary short-term results. Adv Exp Med Biol 528:579–584

  25. 25.

    Elidan J, Cohen E, Levi H, BenEzra D (1991) Effect of cyclosporine A on the hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol 100:464–468

  26. 26.

    Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N (2007) Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 13:1

  27. 27.

    Graykowski EA, Kingman A (1978) Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 7:376–382

  28. 28.

    Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A (1993) A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg 51:243–248

  29. 29.

    Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427

  30. 30.

    Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450

  31. 31.

    Hamuryudan V, Moral F, Yurdakul S et al (1994) Systemic interferon alpha 2b treatment in Behçet’s syndrome. J Rheumatol 21:1098–1100

  32. 32.

    Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656–1662

  33. 33.

    Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet’s disease. J Am Acad Dermatol 24:973–978

  34. 34.

    Kikuchi H, Aramaki K, Hirohata S (2003) Low dose MTX for progressive neuro-Behçet’s disease. A follow-up study for 4 years. Adv Exp Med Biol 528:575–578

  35. 35.

    Kerr AR, Drexel CA, Spielman AI (2003) The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:685–694

  36. 36.

    Kötter I, Günaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486

  37. 37.

    Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon-alpha2a for the treatment of Behçet’s disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 87:423–431

  38. 38.

    Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76

  39. 39.

    Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 20:1093–1096

  40. 40.

    Mat C, Yurdakul S, Ozyazgan Y, Uysal S, Uysal O, Yazıcı H (2006) A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford) 45:348–352

  41. 41.

    Matsuda T, Ohno S, Hirohata S et al (2003) Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs RD 4:19–28

  42. 42.

    Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA (1991) Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 72:425–429

  43. 43.

    Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105

  44. 44.

    Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21(6):824–825

  45. 45.

    Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A (2009) Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol 29:127–133

  46. 46.

    Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368

  47. 47.

    Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243

  48. 48.

    Sakane T, Takeno M, Suziki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1284–1291

  49. 49.

    Saxen MA, Ambrosius WT, Rehemtula al KF, Russell AL, Eckert GJ (1997) Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:356–361

  50. 50.

    Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behçet disease. Ann Intern Med 140:404–406

  51. 51.

    Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46(5):736–741

  52. 52.

    Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behcet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29:267–279

  53. 53.

    Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK (2006) Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 33:541–546

  54. 54.

    Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357

  55. 55.

    Skaare AB, Herlofson BB, Barkvoll P (1996) Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 23:778–781

  56. 56.

    Suda H (1999) Low-dose weekly methotrexate therapy for progressive neuro-Behçet’s disease. Nihon Rinsho Meneki Gakkai Kaishi 22:13–22

  57. 57.

    Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695

  58. 58.

    Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease. An open-label trial. Arthritis Rheum 52:2478–2484

  59. 59.

    Verity DH, Wallace GR, Seed PT et al (1998) Soluble adhesion molecules in Behcet’s disease. Ocul Immunol Inflamm 6:81–92

  60. 60.

    Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322:281–285

  61. 61.

    Yurdakul S, Hamuryudan V, Yazici H (2004) Behcet syndrome. Curr Opin Rheumatol 16:38–42

  62. 62.

    Yurdakul S, Mat C, Tuzun Y et al (2001) A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 44:2686–2692

  63. 63.

    Zouboulis CC, Kötter I, Djawari D et al (1997) Epidemiological features of Adamantiades–Behcet’s disease in Germany and in Europe. Yonsei Med J 38:411–422

Download references

Author information

Correspondence to Erkan Alpsoy.

Additional information

The study was supported by Akdeniz University Scientific Research Projects Unit.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Alpsoy, E., Akman, A. Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301, 693–702 (2009). https://doi.org/10.1007/s00403-009-0990-2

Download citation

Keywords

  • Behçet’s disease
  • Treatment
  • Algorithmic approach
  • Mucocutaneous symptoms
  • Ocular symptoms
  • Articular symptoms
  • Gastrointestinal symptoms
  • Neurologic symptoms